{"organizations": [], "uuid": "b389b68ae25a423d1b333614b77d1cb4b71b9776", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-microport-scientific-corp-sees-30/brief-microport-scientific-corp-sees-30-to-35-increase-in-profit-attributable-for-fy2017-idUSFWN1QI14L", "country": "US", "domain_rank": 408, "title": "BRIEF-Microport Scientific Corp Sees 30% To 35% Increase In Profit Attributable For FY2017", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-02-28T22:10:00.000+02:00", "replies_count": 0, "uuid": "b389b68ae25a423d1b333614b77d1cb4b71b9776"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-microport-scientific-corp-sees-30/brief-microport-scientific-corp-sees-30-to-35-increase-in-profit-attributable-for-fy2017-idUSFWN1QI14L", "ord_in_thread": 0, "title": "BRIEF-Microport Scientific Corp Sees 30% To 35% Increase In Profit Attributable For FY2017", "locations": [], "entities": {"persons": [], "locations": [{"name": "prc", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-microport scientific corp", "sentiment": "negative"}, {"name": "microport scientific corp", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Microport Scientific Corp:\n* SEES 30% TO 35% INCREASE IN PROFIT ATTRIBUTABLE TO EQUITY SHAREHOLDERS OF COMPANY FOR YEAR ENDED 31 DECEMBER 2017\n* INCREASE PROFIT ATTRIBUTABLE DUE TO GROWTH IN REVENUE FROM CARDIOVASCULAR AND ENDOVASCULAR SEGMENTS IN PRC MARKET Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-28T22:10:00.000+02:00", "crawled": "2018-03-01T21:11:07.016+02:00", "highlightTitle": ""}